Monoclonal antibody
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer'"'"'s disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer'"'"'s Disease (AD).
-
Citations
149 Claims
-
1-104. -104. (canceled)
-
105. A monoclonal antibody including any functionally equivalent antibody or functional parts thereof, which antibody recognizes a conformational epitope and binds to polymeric soluble amyloid peptides, oligomeric amyloid peptides, polymeric soluble amyloid Aβ
- peptides and/or oligomeric amyloid Aβ
peptides comprising a plurality of monomeric Aβ
1-42 peptides, respectively. - View Dependent Claims (106, 107, 108, 109, 110, 111, 125, 127, 128, 129, 130, 131, 132, 134, 135, 136, 137, 138, 140, 141, 142, 143, 144, 147, 148)
- peptides and/or oligomeric amyloid Aβ
-
112. A monoclonal antibody including any functionally equivalent antibody or functional parts thereof which antibody has the characteristic properties of an antibody produced by hybridoma cell line EJ1A9, deposited on May 25, 2007 and given deposit number DSM ACC2844.
-
113. A monoclonal antibody including any functionally equivalent antibody or functional parts thereof produced by hybridoma cell line EJ1A9, deposited on May 25, 2007 and given deposit number DSM ACC2844.
-
114. A monoclonal antibody including any functionally equivalent antibody or functional parts thereof, which antibody has been raised against a supramolecular antigenic construct comprising an antigenic peptide corresponding to the amino acid sequence of the β
- -amyloid peptide, Aβ
1-15, modified with hydrophobic palmitic acid moieties, wherein said hydrophobic moiety is covalently bound to each terminus through an amino acid selected from lysine or any other suitable amino acid or amino acid analogue capable of serving as a linker molecule. - View Dependent Claims (133)
- -amyloid peptide, Aβ
-
115. A light chain variable region comprising an amino acid sequence that is 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the sequence set forth in SEQ ID NO:
- 7, or a functional part thereof comprising at least one, at least two, or at least 3 of the light chain CDR having a polypeptide sequence selected from one or more of SEQ ID NOs;
9-11. - View Dependent Claims (121)
- 7, or a functional part thereof comprising at least one, at least two, or at least 3 of the light chain CDR having a polypeptide sequence selected from one or more of SEQ ID NOs;
-
116. A heavy chain variable region comprising an amino acid sequence that is 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the sequence set forth in SEQ ID NO:
- 8, or a functional part thereof comprising at least one, at least two, or at least 3 of the heavy chain CDR having a polypeptide sequence selected from one or more of SEQ ID NOs;
12-14. - View Dependent Claims (122)
- 8, or a functional part thereof comprising at least one, at least two, or at least 3 of the heavy chain CDR having a polypeptide sequence selected from one or more of SEQ ID NOs;
-
117. A monoclonal antibody including any functionally equivalent antibody or functional parts thereof, which antibody comprises a light chain variable domain comprising an amino acid sequence that is 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the sequence set forth in SEQ ID NO:
- 7, or a functional part thereof comprising at least one, at least two, or at least 3 of the light chain CDRs having a polypeptide sequence selected from one or more of SEQ ID NOs;
9-11. - View Dependent Claims (123)
- 7, or a functional part thereof comprising at least one, at least two, or at least 3 of the light chain CDRs having a polypeptide sequence selected from one or more of SEQ ID NOs;
-
118. A monoclonal antibody including any functionally equivalent antibody or functional parts thereof, which antibody comprises a heavy chain variable domain comprising an amino acid sequence that is 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the sequence set forth in SEQ ID NO:
- 8, or a functional part thereof comprising at least one, at least two, or at least 3 of the heavy chain CDRs having a polypeptide sequence selected from one or more of SEQ ID NOs;
12-14. - View Dependent Claims (124)
- 8, or a functional part thereof comprising at least one, at least two, or at least 3 of the heavy chain CDRs having a polypeptide sequence selected from one or more of SEQ ID NOs;
-
119. A monoclonal antibody including any functionally equivalent antibody or functional parts thereof comprising the amino acid sequences of SEQ ID NOs:
- 7-8, wherein the antibody has been altered by introducing at least one, at least two, or at least 3 or more conservative substitutions into the sequences of SEQ ID NOs;
7-8, wherein the antibody essentially maintains its full functionality, and wherein the amino acid in position 52 is selected from any amino acid, from the group consisting of cysteine, tyrosine, and serine, and from cysteine alone. - View Dependent Claims (146)
- 7-8, wherein the antibody has been altered by introducing at least one, at least two, or at least 3 or more conservative substitutions into the sequences of SEQ ID NOs;
-
120. An isolated CDR comprising an amino acid sequence selected from SEQ ID NOs:
- 9-14.
-
126. An isolated polynucleotide comprising at least one of the nucleotide sequences set forth in SEQ ID NOs:
- 15-16.
- View Dependent Claims (149)
-
139. A cell line characterized in that it produces a monoclonal antibody including any functionally equivalent antibody or functional parts thereof which antibody has the characteristic properties of an antibody produced by hybridoma EJ1A9, deposited on May 25, 2007 and given deposit number DSM ACC2844, or wherein the cell line is hybridoma EJ1A9, deposited on May 25, 2007 and given deposit number DSM ACC2844.
-
145. An Aβ
- epitope which is specifically recognized by a monoclonal antibody including any functionally equivalent antibody or functional parts thereof, which antibody has been raised against a supramolecular antigenic construct comprising an antigenic peptide corresponding to the amino acid sequence of the β
-amyloid peptide, Aβ
1-15, modified with hydrophobic palmitic acid moieties, wherein said hydrophobic moiety is covalently bound to each terminus through an amino acid such as, for example, lysine or any other suitable amino acid or amino acid analogue capable of serving as a linker molecule.
- epitope which is specifically recognized by a monoclonal antibody including any functionally equivalent antibody or functional parts thereof, which antibody has been raised against a supramolecular antigenic construct comprising an antigenic peptide corresponding to the amino acid sequence of the β
Specification